Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week High - Here's Why

Key Points

• Amneal Pharmaceuticals shares reached a new 52-week high of $21.25, supported by a generally favorable analyst outlook. Nine analysts rate the stock Buy versus one Sell, with a consensus “Moderate Buy” rating and an average price target of $21.25.
• The company’s latest quarterly results exceeded expectations, reporting $0.30 in EPS versus the $0.24 consensus and $796.2 million in revenue. Analysts expect approximately $0.95 in EPS for the current fiscal year, while management’s FY 2026 guidance calls for $0.96–$1.06 per share.
• Insiders sold 413,016 shares worth about $7.2 million over the past 90 days, while institutional investors own 31.82% of the stock and have generally increased their holdings.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report)'s share price reached a new 52-week high on Tuesday. The stock traded as high as $21.25 and last traded at $21.0340, with a volume of 13,031 shares trading hands. The stock had previously closed at $21.02.

Analyst Ratings Changes

AMRX has been the topic of several recent research reports. Leerink Partners started coverage on Amneal Pharmaceuticals in a report on Wednesday, September 9th. They set an "outperform" rating and a $23.00 price target on the stock. Zacks Research downgraded shares of Amneal Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Tuesday, October 6th. Wall Street Zen upgraded Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. Oppenheimer initiated coverage on Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They set an "outperform" rating and a $27.00 target price for the company. Finally, JPMorgan Chase & Co. raised their price target on shares of Amneal Pharmaceuticals from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Thursday, October 22nd. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $21.25.

Amneal Pharmaceuticals Stock Performance

The company has a market capitalization of $6.78 billion, a price-to-earnings ratio of 43.40, a P/E/G ratio of 2.38 and a beta of 1.22. The company has a 50 day moving average price of $18.81 and a 200 day moving average price of $15.54. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The business had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, EVP Jason Daly sold 210,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the sale, the executive vice president directly owned 35,171 shares of the company's stock, valued at $611,975.40. This represents a 85.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nikita Shah sold 146,403 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the sale, the executive vice president owned 253,390 shares of the company's stock, valued at approximately $4,436,858.90. This represents a 36.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 413,016 shares of company stock worth $7,216,567 over the last 90 days. 17.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently modified their holdings of AMRX. GAMMA Investing LLC raised its position in Amneal Pharmaceuticals by 54.9% during the third quarter. GAMMA Investing LLC now owns 1,605 shares of the company's stock valued at $32,000 after purchasing an additional 569 shares during the period. Fortitude Family Office LLC lifted its stake in shares of Amneal Pharmaceuticals by 100.9% in the third quarter. Fortitude Family Office LLC now owns 1,607 shares of the company's stock worth $32,000 after buying an additional 807 shares in the last quarter. Sterling Capital Management LLC raised its position in Amneal Pharmaceuticals by 30.3% in the third quarter. Sterling Capital Management LLC now owns 3,549 shares of the company's stock valued at $71,000 after purchasing an additional 825 shares during the period. Arizona State Retirement System raised its holdings in shares of Amneal Pharmaceuticals by 1.9% in the 2nd quarter. Arizona State Retirement System now owns 44,011 shares of the company's stock valued at $762,000 after purchasing an additional 837 shares in the last quarter. Finally, Yousif Capital Management LLC raised its position in Amneal Pharmaceuticals by 2.9% in the 3rd quarter. Yousif Capital Management LLC now owns 42,839 shares of the company's stock valued at $863,000 after purchasing an additional 1,197 shares during the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company's generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.